本文選題：TSP-1　切入點(diǎn)：非小細(xì)胞肺癌　出處：《皖南醫(yī)學(xué)院》2017年碩士論文

【摘要】：目的:肺癌大部分為非小細(xì)胞肺癌,發(fā)病率高,確診時(shí)多為晚期。有研究指出血小板反應(yīng)蛋白-1(TSP-1)在肺癌進(jìn)展過程中有不同程度表達(dá),具體表現(xiàn)在抑制細(xì)胞粘附,抑制新生血管的生長及抑制腫瘤生長等方面。本研究通過檢測患者血清TSP-1濃度在非小細(xì)胞肺癌(NSCLC)患者化療前后的表達(dá)程度差異,探討其是否能對非小細(xì)胞肺癌預(yù)后提供臨床評估。方法:實(shí)驗(yàn)組選自2015年10月1日至2016年10月31日,在皖南醫(yī)學(xué)院第一附屬醫(yī)院呼吸內(nèi)科二病區(qū)經(jīng)病理確診為原發(fā)性非小細(xì)胞肺癌并化療治療病人48例�；颊呋煼桨甘且罁�(jù)NCCN指南推薦,綜合患者自身情況的進(jìn)行個體化治療。健康對照組來自同期第一附屬醫(yī)院體檢中心健康體檢者(經(jīng)倫理委員會批準(zhǔn))20例。通過檢測健康組及實(shí)驗(yàn)組肺癌患者首次化療前、第三次化療前、第五次化療前的血清TSP-1的濃度值(具體操作是抽取病人入院第二天清晨空腹靜脈血),于化療4周期結(jié)束后評估化療療效,觀察化療療效與TSP-1濃度之間是否存在關(guān)聯(lián)。收集資料具體內(nèi)容包括年齡、性別、吸煙史、血常規(guī)、血凝常規(guī)、腫瘤標(biāo)記物、病理類型、體力狀況評分、病情評估資料、化療方法等。結(jié)果:一、將實(shí)驗(yàn)組和對照組血小板計(jì)數(shù)進(jìn)行組間差異比較發(fā)現(xiàn)P值大于0.05,實(shí)驗(yàn)組血凝常規(guī)完全正常和不完全正常的患者TSP-1濃度值差異無意義。二、對照組與實(shí)驗(yàn)組TSP-1濃度比較,NSCLC患者首次化療前、第三次化療前、第五次化療前血清TSP-1濃度顯著低于健康對照組(P0.01);三、按照患者病情評估資料將實(shí)驗(yàn)組具體分為CR(完全緩解,0例)組、PR(部分緩解,20例)組、SD(病情穩(wěn)定,18例)組、PD(病情進(jìn)展,10例)組。比較三組在首次化療前、第三次化療前、第五次化療前血清TSP-1濃度,發(fā)現(xiàn)PR組TSP-1濃度呈現(xiàn)遞增趨勢(P0.01),SD組化療前后TSP-1濃度差異變化不明顯(P0.05),PD組TSP-1濃度值呈現(xiàn)遞減趨勢(P0.01);比較首次化療前、第三次化療前、第五次化療前的PR組、SD組、PD組差異,發(fā)現(xiàn)首次化療前、第三次化療前TSP-1血清濃度差異P值大于0.05,第五次化療前TSP-1濃度三組差異P值小于0.01。結(jié)論:NSCLC血清中TSP-1濃度明顯低于正常人群,其濃度的升高與降低趨勢與患者化療療效評價(jià)一致。血清TSP-1濃度可為NSCLC的預(yù)后提供臨床價(jià)值。
[Abstract]:Objective: the majority of lung cancer is non-small cell lung cancer, the incidence is high, the diagnosis is more advanced.The purpose of this study was to detect the expression of serum TSP-1 in patients with non-small cell lung cancer (NSCLC) before and after chemotherapy, and to explore whether it could provide a clinical evaluation for the prognosis of NSCLC.Methods: from October 1, 2015 to October 31, 2016, 48 patients with primary non-small cell lung cancer were pathologically diagnosed as primary non-small cell lung cancer and treated with chemotherapy in Department of Respiratory Medicine, the first affiliated Hospital of Southern Anhui Medical College.Patient chemotherapy regimen is based on the NCCN guidelines, comprehensive individual treatment of their own conditions.The healthy control group came from the first affiliated hospital in the same period (20 cases were approved by the Ethics Committee).Before the first chemotherapy and the third chemotherapy, the lung cancer patients in the healthy group and the experimental group were detected.The concentration of serum TSP-1 before the fifth chemotherapy (the operation was to extract the fasting venous blood of the patient on the second day after admission, to evaluate the effect of chemotherapy after 4 cycles of chemotherapy, and to observe whether there was a correlation between the curative effect of chemotherapy and the concentration of TSP-1.The data included age, sex, smoking history, blood routine, hemagglutination routine, tumor marker, pathological type, physical status score, disease evaluation data, chemotherapy methods and so on.Results: first, the difference of platelet count between the experimental group and the control group showed that P value was greater than 0.05, and the TSP-1 concentration of the patients with complete normal and incomplete hemagglutination in the experimental group had no significance.2. The concentration of serum TSP-1 in the control group and the experimental group was significantly lower than that in the control group before the first chemotherapy, before the third chemotherapy, and before the fifth chemotherapy.According to the evaluation data of the patients, the experimental group was divided into two groups: group R (0 cases of complete remission) and group P (20 cases of partial remission), group D (18 cases of stable disease) and group D (10 cases of disease progression).The levels of serum TSP-1 were compared before the first chemotherapy, before the third chemotherapy and before the fifth chemotherapy in the three groups.It was found that before the first chemotherapy, the difference of TSP-1 serum concentration was greater than 0.05 before the third chemotherapy, and the difference P value of the three groups before the fifth chemotherapy was less than 0.01.Serum TSP-1 concentration can provide clinical value for prognosis of NSCLC.
【學(xué)位授予單位】：皖南醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R734.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張瑩瑩;王榮麗;;Survivin與肺部疾病關(guān)系的研究進(jìn)展[J];西南軍醫(yī);2016年05期

2 李放;謝雙華;王剛;蘇凱;馮小雙;呂章艷;郭蘭偉;陳朔華;昌盛;陳玉恒;任建松;石菊芳;楊文靜;崔宏;吳壽嶺;代敏;李霓;赫捷;;BMI與吸煙男性肺癌發(fā)病關(guān)系的前瞻性隊(duì)列研究[J];中華預(yù)防醫(yī)學(xué)雜志;2016年05期

3 馬巖;宋揚(yáng);王鐵君;賈曉晶;陳志深;宋雪;;大劑量奧施康定聯(lián)合減癥放療等綜合治療晚期肺癌伴癌痛患者1例[J];現(xiàn)代腫瘤醫(yī)學(xué);2016年12期

4 楊萬全;王懇;;參附注射液治療晚期肺癌氣虛證的臨床研究[J];中醫(yī)臨床研究;2016年08期

5 李卉;;胸腔內(nèi)局部化療聯(lián)合中藥治療肺癌胸水療效觀察[J];中外醫(yī)學(xué)研究;2016年07期

6 李繼恩;姜在鵬;喬明亮;;不同的放療方法對肺癌骨轉(zhuǎn)移的療效對比分析[J];醫(yī)學(xué)理論與實(shí)踐;2016年04期

7 王俊龍;解晨昊;;全腦放療聯(lián)合化療及聯(lián)合吉非替尼靶向治療晚期非小細(xì)胞肺癌腦轉(zhuǎn)移[J];中國實(shí)用醫(yī)刊;2016年02期

8 宮艷美;李文斌;;吉西他濱配合中藥治療老年晚期非小細(xì)胞肺癌的效果[J];中國實(shí)用醫(yī)刊;2016年02期

9 陳峰;;放療聯(lián)合唑來膦酸治療惡性腫瘤骨轉(zhuǎn)移效果的臨床觀察[J];中國現(xiàn)代藥物應(yīng)用;2014年06期

10 劉丹;白沖;;血清癌胚抗原與非小細(xì)胞肺癌關(guān)系的研究進(jìn)展[J];國際呼吸雜志;2012年15期

相關(guān)碩士學(xué)位論文 前1條

1 胡秀峰;食管鱗癌患者化療前后血清TSP-1、VEGF水平變化及其臨床意義[D];鄭州大學(xué);2006年

，

本文編號：1710489